This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hayman, J. A. Articles by Lichter, A. S. Search for Related Content PubMed PubMed Citation Articles by Hayman, J. A. Articles by Lichter, A. S. Social Bookmarking                            What's this?

Dose Escalation in Non–Small-Cell Lung Cancer Using Three-Dimensional Conformal Radiation Therapy: Update of a Phase I Trial

From the Departments of Radiation Oncology and Internal Medicine, Division of Hematology/Oncology, University of Michigan Health System, Ann Arbor, MI, and Department of Radiation Oncology, Medical University of South Carolina, Charleston, SC.

Address reprint requests to James A. Hayman, MD, Department of Radiation Oncology, University of Michigan, UH-B2C490, Box 0010, 1500 East Medical Center Dr, Ann Arbor, MI 48109; email hayman{at}umich.edu

PURPOSE: High-dose radiation may improve outcomes in non–small-cell lung cancer (NSCLC). By using three-dimensional conformal radiation therapy and limiting the target volume, we hypothesized that the dose could be safely escalated.

MATERIALS AND METHODS: A standard phase I design was used. Five bins were created based on the volume of normal lung irradiated, and dose levels within bins were chosen based on the estimated risk of radiation pneumonitis. Starting doses ranged from 63 to 84 Gy given in 2.1-Gy fractions. Target volumes included the primary tumor and any nodes 1 cm on computed tomography. Clinically uninvolved nodal regions were not included purposely. More recently, selected patients received neoadjuvant cisplatin and vinorelbine.

RESULTS: At the time of this writing, 104 patients had been enrolled. Twenty-four had stage I, four had stage II, 43 had stage IIIA, 26 had stage IIIB, and seven had locally recurrent disease. Twenty-five received chemotherapy, and 63 were assessable for escalation. All bins were escalated at least twice. Although grade 2 radiation pneumonitis occurred in five patients, grade 3 radiation pneumonitis occurred in only two. The maximum-tolerated dose was only established for the largest bin, at 65.1 Gy. Dose levels for the four remaining bins were 102.9, 102.9, 84 and 75.6 Gy. The majority of patients failed distantly, though a significant proportion also failed in the target volume. There were no isolated failures in clinically uninvolved nodal regions.

CONCLUSION: Dose escalation in NSCLC has been accomplished safely in most patients using three-dimensional conformal radiation therapy, limiting target volumes, and segregating patients by the volume of normal lung irradiated.

Presented at the Thirty-Fifth Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, May 15-18, 1999.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. P. van Meerbeeck, S. Meersschout, R. De Pauw, I. Madani, and W. De Neve Modern Radiotherapy as Part of Combined Modality Treatment in Locally Advanced Non-Small Cell Lung Cancer: Present Status and Future Prospects Oncologist, June 1, 2008; 13(6): 700 - 708. [Abstract] [Full Text] [PDF]

				K. E. Rosenzweig, S. Sura, A. Jackson, and E. Yorke Involved-Field Radiation Therapy for Inoperable Non Small-Cell Lung Cancer J. Clin. Oncol., December 10, 2007; 25(35): 5557 - 5561. [Abstract] [Full Text] [PDF]

				T. E. Stinchcombe, D. Fried, D. E. Morris, and M. A. Socinski Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer Oncologist, July 1, 2006; 11(7): 809 - 823. [Abstract] [Full Text] [PDF]

				J. A. Bogart, S. L. Seagren, and A. Glicksman Radiation oncology research in the cancer and leukemia group B. Clin. Cancer Res., June 1, 2006; 12(11): 3628s - 3634s. [Abstract] [Full Text] [PDF]

				P. van Luijk, A. Novakova-Jiresova, H. Faber, J. M. Schippers, H. H. Kampinga, H. Meertens, and R. P. Coppes Radiation Damage to the Heart Enhances Early Radiation-Induced Lung Function Loss Cancer Res., August 1, 2005; 65(15): 6509 - 6511. [Abstract] [Full Text] [PDF]

				C. P. Belani, W. Wang, D. H. Johnson, H. Wagner, J. Schiller, M. Veeder, and M. Mehta Phase III Study of the Eastern Cooperative Oncology Group (ECOG 2597): Induction Chemotherapy Followed by Either Standard Thoracic Radiotherapy or Hyperfractionated Accelerated Radiotherapy for Patients With Unresectable Stage IIIA and B Non-Small-Cell Lung Cancer J. Clin. Oncol., June 1, 2005; 23(16): 3760 - 3767. [Abstract] [Full Text] [PDF]

				L. B. Marks, J. Garst, M. A. Socinski, G. Sibley, A. W. Blackstock, J. E. H. S. Zhou, T. Shafman, A. Tisch, R. Clough, X. Yu, et al. Carboplatin/Paclitaxel or Carboplatin/Vinorelbine Followed by Accelerated Hyperfractionated Conformal Radiation Therapy: Report of a Prospective Phase I Dose Escalation Trial From the Carolina Conformal Therapy Consortium J. Clin. Oncol., November 1, 2004; 22(21): 4329 - 4340. [Abstract] [Full Text] [PDF]

				M. A. Socinski, D. E. Morris, J. S. Halle, D. T. Moore, T. A. Hensing, S. A. Limentani, R. Fraser, M. Tynan, A. Mears, M. P. Rivera, et al. Induction and Concurrent Chemotherapy With High-Dose Thoracic Conformal Radiation Therapy in Unresectable Stage IIIA and IIIB Non-Small-Cell Lung Cancer: A Dose-Escalation Phase I Trial J. Clin. Oncol., November 1, 2004; 22(21): 4341 - 4350. [Abstract] [Full Text] [PDF]

				F. C. Detterbeck, J. F. Vansteenkiste, D. E. Morris, C. A. Dooms, A. H. Khandani, and M. A. Socinski Seeking a Home for a PET, Part 3: Emerging Applications of Positron Emission Tomography Imaging in the Management of Patients With Lung Cancer Chest, November 1, 2004; 126(5): 1656 - 1666. [Abstract] [Full Text] [PDF]

				B. Movsas, J. Moughan, R. Komaki, H. Choy, R. Byhardt, C. Langer, M. Goldberg, M. Graham, D. Ettinger, D. Johnstone, et al. Radiotherapy Patterns of Care Study in Lung Carcinoma J. Clin. Oncol., December 15, 2003; 21(24): 4553 - 4559. [Abstract] [Full Text] [PDF]

				G. V. Scagliotti and A. T. Turrisi III Docetaxel-Based Combined-Modality Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer Oncologist, August 1, 2003; 8(4): 361 - 374. [Abstract] [Full Text] [PDF]

				A Price Lung cancer * 5: State of the art radiotherapy for lung cancer Thorax, May 1, 2003; 58(5): 447 - 452. [Abstract] [Full Text] [PDF]

				B. Jeremic, J. Classen, M. Bamberg, and R. McGarry Observation-Only Management of Inoperable Lung Cancer: Do Not Do That: A Loud and Clear Radiographic Point of View! Chest, January 1, 2003; 123(1): 313 - 315. [Full Text] [PDF]

				S. G. Spiro and J. C. Porter Lung Cancer--Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1166 - 1196. [Abstract] [Full Text] [PDF]

				M. S. Anscher, L. B. Marks, T. D. Shafman, R. Clough, H. Huang, A. Tisch, M. Munley, J. E. Herndon II, J. Garst, J. Crawford, et al. Using Plasma Transforming Growth Factor Beta-1 During Radiotherapy to Select Patients for Dose Escalation J. Clin. Oncol., September 1, 2001; 19(17): 3758 - 3765. [Abstract] [Full Text] [PDF]